Local use of dexamethasone in the treatment of ocular myasthenia gravis
Abstract Background At present, patients with ocular myasthenia gravis (OMG) are typically treated with systemic drugs. We investigated the use of dexamethasone injected in the peribulbar region or extraocular muscle to treat patients with OMG. Methods Patients with OMG were given dexamethasone via...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2020-10-01
|
| Series: | BMC Ophthalmology |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12886-020-01697-2 |
| _version_ | 1818192330014851072 |
|---|---|
| author | Minghua Shi Yingjia Ye Junping Zhou Aijiao Qin Jing Cheng Hongxing Ren |
| author_facet | Minghua Shi Yingjia Ye Junping Zhou Aijiao Qin Jing Cheng Hongxing Ren |
| author_sort | Minghua Shi |
| collection | DOAJ |
| description | Abstract Background At present, patients with ocular myasthenia gravis (OMG) are typically treated with systemic drugs. We investigated the use of dexamethasone injected in the peribulbar region or extraocular muscle to treat patients with OMG. Methods Patients with OMG were given dexamethasone via peribulbar injection or direct injection into the main paralyzed extraocular muscles, once a week, for 4–6 weeks. The severity of diplopia, blepharoptosis, eye position, and eye movement were evaluated before and after treatment. The duration of follow-up time was ≥6 months. Results Among the 14 patients with OMG who received this treatment, mean age was 38.7 ± 29.7 years. After treatment, symptoms were relieved in 12 patients (85.7%), 1 patient (7.1%) had partial response to treatment, and 1 patient (7.1%) had no response. Two patients (14.2%) experienced symptom recurrence during the follow-up period. Conclusions Dexamethasone peribulbar or extraocular muscle injection is effective in the treatment of patients with OMG and may replace systemic drug therapy. Trial registration Chinese Clinical Trial Registry, ChiCTR2000038863 , October 7, 2020.Retrospectively registered. |
| first_indexed | 2024-12-12T00:28:47Z |
| format | Article |
| id | doaj.art-c0efe32eae764a0c81f8a2d1fec78fff |
| institution | Directory Open Access Journal |
| issn | 1471-2415 |
| language | English |
| last_indexed | 2024-12-12T00:28:47Z |
| publishDate | 2020-10-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Ophthalmology |
| spelling | doaj.art-c0efe32eae764a0c81f8a2d1fec78fff2022-12-22T00:44:32ZengBMCBMC Ophthalmology1471-24152020-10-012011910.1186/s12886-020-01697-2Local use of dexamethasone in the treatment of ocular myasthenia gravisMinghua Shi0Yingjia Ye1Junping Zhou2Aijiao Qin3Jing Cheng4Hongxing Ren5Department of Strabismus and Pediatric Ophthalmology, Wuhan Aier Eye Hospital (Hanyang)Department of Strabismus and Pediatric Ophthalmology, Wuhan Aier Eye Hospital (Hanyang)Department of Strabismus and Pediatric Ophthalmology, Wuhan Aier Eye Hospital (Hanyang)Department of Strabismus and Pediatric Ophthalmology, Wuhan Aier Eye Hospital (Hanyang)Department of Strabismus and Pediatric Ophthalmology, Wuhan Aier Eye Hospital (Hanyang)Department of Strabismus and Pediatric Ophthalmology, Wuhan Aier Eye Hospital (Hanyang)Abstract Background At present, patients with ocular myasthenia gravis (OMG) are typically treated with systemic drugs. We investigated the use of dexamethasone injected in the peribulbar region or extraocular muscle to treat patients with OMG. Methods Patients with OMG were given dexamethasone via peribulbar injection or direct injection into the main paralyzed extraocular muscles, once a week, for 4–6 weeks. The severity of diplopia, blepharoptosis, eye position, and eye movement were evaluated before and after treatment. The duration of follow-up time was ≥6 months. Results Among the 14 patients with OMG who received this treatment, mean age was 38.7 ± 29.7 years. After treatment, symptoms were relieved in 12 patients (85.7%), 1 patient (7.1%) had partial response to treatment, and 1 patient (7.1%) had no response. Two patients (14.2%) experienced symptom recurrence during the follow-up period. Conclusions Dexamethasone peribulbar or extraocular muscle injection is effective in the treatment of patients with OMG and may replace systemic drug therapy. Trial registration Chinese Clinical Trial Registry, ChiCTR2000038863 , October 7, 2020.Retrospectively registered.http://link.springer.com/article/10.1186/s12886-020-01697-2Ocular myasthenia gravisStrabismusCorticosteroidsDexamethasoneLocal injection |
| spellingShingle | Minghua Shi Yingjia Ye Junping Zhou Aijiao Qin Jing Cheng Hongxing Ren Local use of dexamethasone in the treatment of ocular myasthenia gravis BMC Ophthalmology Ocular myasthenia gravis Strabismus Corticosteroids Dexamethasone Local injection |
| title | Local use of dexamethasone in the treatment of ocular myasthenia gravis |
| title_full | Local use of dexamethasone in the treatment of ocular myasthenia gravis |
| title_fullStr | Local use of dexamethasone in the treatment of ocular myasthenia gravis |
| title_full_unstemmed | Local use of dexamethasone in the treatment of ocular myasthenia gravis |
| title_short | Local use of dexamethasone in the treatment of ocular myasthenia gravis |
| title_sort | local use of dexamethasone in the treatment of ocular myasthenia gravis |
| topic | Ocular myasthenia gravis Strabismus Corticosteroids Dexamethasone Local injection |
| url | http://link.springer.com/article/10.1186/s12886-020-01697-2 |
| work_keys_str_mv | AT minghuashi localuseofdexamethasoneinthetreatmentofocularmyastheniagravis AT yingjiaye localuseofdexamethasoneinthetreatmentofocularmyastheniagravis AT junpingzhou localuseofdexamethasoneinthetreatmentofocularmyastheniagravis AT aijiaoqin localuseofdexamethasoneinthetreatmentofocularmyastheniagravis AT jingcheng localuseofdexamethasoneinthetreatmentofocularmyastheniagravis AT hongxingren localuseofdexamethasoneinthetreatmentofocularmyastheniagravis |